Literature DB >> 305267

Immunologic abnormalities in an animal model of chronic hypoplastic marrow failure induced by busulfan.

C A Pugsley, I J Forbes, A A Morley.   

Abstract

The immunology of chronic hypoplastic marrow failure (CHMF, aplastic anemia) was studied in an experimental murine model of the disease induced by busulfan. B lymphocytes of peripheral blood, spleen, and bone marrow were reduced to 30%-40% and T lymphocytes of thymus, spleen, marrow, and blood were decreased to 20%-70% of control values. IgG and IgM antibody titer to sheep red blood cells were reduced to one-third of control levels, and splenic IgG, but not IgM, plaque-forming cells were fewer on day 7 after antigen stimulation. The proliferative responses to phytohemagglutinin or concanavalin A were reduced in cultures of peripheral blood lymphocytes, splenic lymphocytes, and thymocytes, and cutaneous delayed-type hypersensitivity induced by dinitrofluorobenze was not detected in mice with CHMF. The results demonstrate disturbance of a variety of cellular and humoral functions and suggest that the disturbance was due to quantitative and possibly qualitative abnormalities of the cell types subserving these functions. The results suggest that residual cell injury, the lesion underlying experimental CHMF, is not confined to the myeloid stem cell but also involved cells of the lymphoid series.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 305267

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Further development of a model of chronic bone marrow aplasia in the busulphan-treated mouse.

Authors:  John A Turton; William R Sones; Charles M Andrews; Andrew M Pilling; Thomas C Williams; Gemma Molyneux; Sian Rizzo; Edward C Gordon-Smith; Frances M Gibson
Journal:  Int J Exp Pathol       Date:  2006-02       Impact factor: 1.925

2.  The haemotoxicity of mitomycin in a repeat dose study in the female CD-1 mouse.

Authors:  Gemma Molyneux; Frances M Gibson; Edward C Gordon-Smith; Andrew M Pilling; Kai Chiu Liu; Sian Rizzo; Susan Sulsh; John A Turton
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

Review 3.  Animal models for acquired bone marrow failure syndromes.

Authors:  Jichun Chen
Journal:  Clin Med Res       Date:  2005-05

4.  Residual effects of busulfan and irradiation on murine hematopoietic stem and progenitor cells.

Authors:  Kaylind Batey; Jisoo Kim; Lauren Brinster; Gladys Gonzalez-Matias; Zhijie Wu; Sabrina Solorzano; Jichun Chen; Xingmin Feng; Neal S Young
Journal:  Exp Hematol       Date:  2021-11-08       Impact factor: 3.084

5.  Ectopic bone marrow development in experimental busulfan-induced hypoplastic anemia in mice.

Authors:  N M Ideriha; I Vugman; R P Falcão
Journal:  Blut       Date:  1984-05

6.  Serum FLT-3 ligand in a busulphan-induced model of chronic bone marrow hypoplasia in the female CD-1 mouse.

Authors:  Gemma Molyneux; Frances M Gibson; Matthew Whayman; John A Turton
Journal:  Int J Exp Pathol       Date:  2008-04       Impact factor: 1.925

7.  Busulfan and chloramphenicol induced T cell lymphoma: cell surface characteristics and functional properties.

Authors:  N Bhoopalam; K Price; H Norgello; J Barone-Varelas; W Fried
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

8.  Primitive Sca-1 Positive Bone Marrow HSC in Mouse Model of Aplastic Anemia: A Comparative Study through Flowcytometric Analysis and Scanning Electron Microscopy.

Authors:  Sumanta Chatterjee; Pratima Basak; Prosun Das; Madhurima Das; Jacintha Archana Pereira; Ranjan Kumar Dutta; Malay Chaklader; Samaresh Chaudhuri; Sujata Law
Journal:  Stem Cells Int       Date:  2009-10-28       Impact factor: 5.443

Review 9.  Mesenchymal Stem Cell Benefits Observed in Bone Marrow Failure and Acquired Aplastic Anemia.

Authors:  Vivian Fonseca Gonzaga; Cristiane Valverde Wenceslau; Gustavo Sabino Lisboa; Eduardo Osório Frare; Irina Kerkis
Journal:  Stem Cells Int       Date:  2017-12-03       Impact factor: 5.443

10.  CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia.

Authors:  Shihong Lu; Meili Ge; Yizhou Zheng; Jianping Li; Xiaoming Feng; Sizhou Feng; Jinbo Huang; Ying Feng; Donglin Yang; Jun Shi; Fang Chen; Zhongchao Han
Journal:  Stem Cell Res Ther       Date:  2017-08-01       Impact factor: 6.832

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.